CLAIMS

1. A liquid pharmaceutical gonadotropin formulation, comprising a gonadotropin, arginine in an amount of from 50 to 160 mM, and methionine in an amount of from 0.05 to 1.5 mg/ml, wherein the formulation does not comprise an additional buffer, and wherein the pH of the formulation is between 6.0 and 7.5.

2. The pharmaceutical formulation of claim 1, wherein the gonadotropin comprises hCG (human chorionic gonadotropin), and optionally FSH and/or LH.

3. The pharmaceutical formulation of claim 1 or 2, wherein the gonadotropin comprises hMG (human menopausal gonadotropin).

4. The pharmaceutical formulation of any one of claims 1 to 3, wherein the gonadotropin comprises human origin, urinary-derived FSH, LH and/or hCG.

5. The pharmaceutical formulation of any one of claims 1 to 3, wherein the gonadotropin comprises recombinant FSH, LH and/or hCG.

6. The pharmaceutical formulation of any one of the preceding claims, additionally comprising a preservative, preferably phenol.

7. The pharmaceutical formulation of any one of the preceding claims, additionally comprising a surface-active agent, preferably a polysorbate, even more preferably polysorbate 20.

8. The pharmaceutical formulation of claim 6 or 7, wherein the preservative, preferably the phenol, is comprised in an amount of 4 – 6 mg/ml, preferably in an amount of 5 mg/ml.

9. The pharmaceutical formulation of claim 7 or 8, wherein the surface-active agent, preferably the polysorbate 20, is comprised in an amount of 0.001 – 0.05 mg/ml, preferably in an amount of 0.005 mg/ml.

10. The pharmaceutical formulation of any one of the preceding claims, wherein the arginine is preferably L-arginine HCl.

11. The pharmaceutical formulation of any one of the preceding claims, wherein the hMG is comprised in an amount of 300 – 900, preferably 500 – 700, IU/ml.

12. The pharmaceutical formulation of any one of the preceding claims, which consists of
    - 625 IU/ml hMG
    - 0.15 mg/ml Methionine
    - 150 mM arginine
    - 5 mg/ml phenol
    - 0.005 mg/ml polysorbate 20

- Water for injection (WFI), and
- wherein the formulation has a pH of 6.8 +/- 0.3.

13. A liquid pharmaceutical formulation as described in any one of the preceding claims, for use in a method of treatment of infertility.

14. The pharmaceutical formulation for use according to claim 13, wherein the treatment is a treatment of ovulation induction (OI), assisted reproductive techniques (ART), and/or hypogonadotrophic hypogonadism in men.

15. A method for stabilization of a liquid pharmaceutical formulation, comprising hMG, which comprises the step of
    - Providing a sample of urine from a human woman,
    - Extracting hMG from the sample,
    - Compounding said extract with arginine and methionine, in amounts as defined in claim 1,
    - Optionally further adding phenol and polysorbate in amounts as defined in claims 8 and 9, respectively,
    - Adjusting the pH of the formulation to between 6.0 and 7.5,
    - wherein no additional buffer is added.

16. Use of a liquid pharmaceutical formulation as described in any one of claims 1-12, in the manufacture of a medicament for the treatment of infertility.

17. The use of claim 16, wherein the treatment is a treatment of ovulation induction (OI), assisted reproductive techniques (ART), and/or hypogonadotrophic hypogonadism in men.